Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma

Summary

This study will evaluate the safety and efficacy of high-dose rituximab combined with temozolomide in the treatment of patients with Primary Central Nervous System Lymphomas (PCNSL). This novel combination will be evaluated in PCNSL patients who are 60 years of age or older, or in patients 18 years or older who refuse methotrexate-based treatment.

Timeline

Start

2014-07

Primary completion

2016-02

Completion

2016-02

Outcome

Outcome not reported

Stopped (Enrollment): “Closed early due to slow accrual.”

Drugs

Indications